
Remibrutinib reduced relapse rates and improved disease progression rates

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

The new centre will be home to nearly 2,000 world-class researchers and scientists

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

The results from a global phase 3 trial show the longest survival data ever reported in this setting

MS affects nearly three million people worldwide and has three main types

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

There are currently no approved human vaccines for Lyme disease

The treatments are for eligible adults in England and Wales

More than 186,000 men are diagnosed each year with mHSPC globally

Litfulo delivered significant, clinically meaningful improvements for both face and body